Skip to main content
. Author manuscript; available in PMC: 2020 Oct 30.
Published in final edited form as: Leukemia. 2020 Jan 27;34(7):1816–1827. doi: 10.1038/s41375-020-0710-7

Figure 3.

Figure 3.

Cells with TP53mut have survival advantage under drug pressure and have higher leukemia stem cells percentage.

(A) Left: Flow diagram showing the experimental procedures. Right: MTS assay in TP53wt and mutant cells after 72h Ara-C treatment. (B) Top: Flow diagram showing the experimental procedures. Bottom: Single cell clones of MV4–11 TP53wt and TP53mut labeled with GFP were first tested by FACS separately. Then cells were mixed and treated with either vehicle or Ara-C and tested by FACS on day 5. (C) Top: Flow diagram showing the experimental design. Middle and bottom: cells from bone marrow or spleen were gated for hCD45 positive and tested for GFP signal. Results were summarized in the right panel. Bars indicate the standard error of mean. *P < 0.05 (D) Cells were analyzed by FACS for LSC markers.